Alx Oncology Holdings (ALXO) EBITDA (2019 - 2026)

Alx Oncology Holdings has disclosed EBITDA across 8 years of filings, most recently posting -$19.0 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$19.0 million, up 40.4% year-over-year; the trailing twelve-month figure through Mar 2026 was -$91.2 million (up 33.22% YoY), and the FY2025 annual result was -$104.0 million, up 26.99% from the prior year.
• EBITDA came in at -$19.0 million for Q1 2026 at Alx Oncology Holdings, up from -$23.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $88.5 million in Q4 2023 to a low of -$53.3 million in Q3 2023.
• The 5-year median for EBITDA is -$32.2 million (2023), against an average of -$25.0 million.
• Across the five-year window, EBITDA surged 374.64% in 2023 and sank 134.6% in 2024, its largest moves.
• Alx Oncology Holdings' EBITDA stood at -$32.2 million in 2022, then surged by 374.64% to $88.5 million in 2023, then tumbled by 134.6% to -$30.6 million in 2024, then rose by 24.8% to -$23.0 million in 2025, then rose by 17.61% to -$19.0 million in 2026.
• The last three EBITDA figures came in at -$19.0 million (Q1 2026), -$23.0 million (Q4 2025), and -$22.5 million (Q3 2025), per Business Quant data.